title: Inhibition of inflammatory gene expression in keratinocytes using a composition containing carnitine, thioctic Acid and saw palmetto extract.
abstract: Chronic inflammation of the hair follicle (HF) is considered a contributing factor in the pathogenesis of androgenetic alopecia (AGA). Previously, we clinically tested liposterolic extract of Serenoa repens (LSESr) and its glycoside, β-sitosterol, in subjects with AGA and showed a highly positive response to treatment. In this study, we sought to determine whether blockade of inflammation using a composition containing LSESr as well as two anti-inflammatory agents (carnitine and thioctic acid) could alter the expression of molecular markers of inflammation in a well-established in vitro system. Using a well-validated assay representative of HF keratinocytes, specifically, stimulation of cultured human keratinocyte cells in vitro, we measured changes in gene expression of a spectrum of well-known inflammatory markers. Lipopolysaccharide (LPS) provided an inflammatory stimulus. In particular, we found that the composition effectively suppressed LPS-activated gene expression of chemokines, including CCL17, CXCL6 and LTB(4) associated with pathways involved in inflammation and apoptosis. Our data support the hypothesis that the test compound exhibits anti-inflammatory characteristics in a well-established in vitro assay representing HF keratinocyte gene expression. These findings suggest that 5-alpha reductase inhibitors combined with blockade of inflammatory processes could represent a novel two-pronged approach in the treatment of AGA with improved efficacy over current modalities.
authors.affiliation: State University of New York (SUNY), Albany, NY, USA.
authors.forename: Sridar
authors.initials: S
authors.lastname: Chittur
authors.forename: Brian
authors.initials: B
authors.lastname: Parr
authors.forename: Geno
authors.initials: G
authors.lastname: Marcovici
references.citation: Expert Opin Pharmacother. 2004 Apr;5(4):933-40
references.pmid: 15102575
references.citation: J Urol. 1992 May;147(5):1298-302
references.pmid: 1373779
references.citation: Ross Fiziol Zh Im I M Sechenova. 2005 Dec;91(12):1469-80
references.pmid: 16493928
references.citation: Drugs Aging. 1996 Nov;9(5):379-95
references.pmid: 8922564
references.citation: Biol Pharm Bull. 2007 Jan;30(1):21-6
references.pmid: 17202653
references.citation: Inflamm Bowel Dis. 2006 Jul;12(7):612-8
references.pmid: 16804399
references.citation: Int J Food Microbiol. 2009 Apr 30;131(1):40-51
references.pmid: 19264370
references.citation: Oncol Rep. 2007 Mar;17(3):573-7
references.pmid: 17273735
references.citation: Evid Based Complement Alternat Med. 2006 Dec;3(4):447-57
references.pmid: 17173108
references.citation: Nihon Shinkei Seishin Yakurigaku Zasshi. 2008 Jun;28(3):113-20
references.pmid: 18646596
references.citation: J Urol. 2004 Nov;172(5 Pt 1):1792-9
references.pmid: 15540722
references.citation: Am J Pathol. 2003 Mar;162(3):803-14
references.pmid: 12598315
references.citation: Dermatology. 2007;214(2):125-9
references.pmid: 17341860
references.citation: Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43
references.pmid: 19002123
references.citation: Toxicology. 2008 Jul 30;249(2-3):167-75
references.pmid: 18571826
references.citation: J Dermatol Sci. 2005 May;38(2):89-97
references.pmid: 15862941
references.citation: Arch Esp Urol. 1994 Nov;47(9):883-7; discussion 887-8
references.pmid: 7530944
references.citation: Skin Pharmacol. 1996;9(6):366-75
references.pmid: 9055357
references.citation: Int J Cancer. 2005 Mar 20;114(2):190-4
references.pmid: 15543614
references.citation: Arch Dermatol Res. 2009 Jun;301(5):381-5
references.pmid: 19277688
references.citation: J Cosmet Dermatol. 2008 Mar;7(1):78-82
references.pmid: 18254816
references.citation: Rev Invest Clin. 2008 Jan-Feb;60(1):58-67
references.pmid: 18589588
references.citation: Clin Interv Aging. 2006;1(3):261-5
references.pmid: 18046879
references.citation: J Mol Med (Berl). 2006 Jan;84(1):75-87
references.pmid: 16388388
references.citation: Clin Ther. 2007 Mar;29(3):387-98
references.pmid: 17577460
references.citation: Exp Gerontol. 2002 Aug-Sep;37(8-9):981-90
references.pmid: 12213548
references.citation: Am J Med. 2008 Oct;121(10 Suppl 1):S21-31
references.pmid: 18926166
references.citation: Mech Ageing Dev. 2004 Jul;125(7):507-12
references.pmid: 15246746
references.citation: Comp Funct Genomics. 2003;4(1):47-55
references.pmid: 18629100
references.citation: Endocr Metab Immune Disord Drug Targets. 2008 Jun;8(2):132-42
references.pmid: 18537699
references.citation: Planta Med. 2001 Aug;67(6):489-500
references.pmid: 11509966
references.citation: J Altern Complement Med. 2002 Apr;8(2):143-52
references.pmid: 12006122
references.citation: Chem Immunol Allergy. 2007;93:181-194
references.pmid: 17369706
references.citation: Evid Based Complement Alternat Med. 2010 Sep;7(3):367-73
references.pmid: 18955318
references.citation: Dermatology. 2003;206(3):189-91
references.pmid: 12673073
references.citation: J Steroid Biochem Mol Biol. 1994 Mar;48(4):347-52
references.pmid: 8142312
references.citation: Vet Res Commun. 2008 Dec;32(8):647-57
references.pmid: 18566907
references.citation: Toxicology. 2006 Feb 1;218(2-3):90-9
references.pmid: 16289751
references.citation: Expert Opin Investig Drugs. 1999 Apr;8(4):403-15
references.pmid: 15992088
references.citation: J Am Acad Dermatol. 1998 Oct;39(4 Pt 1):578-89
references.pmid: 9777765
references.citation: Cytokine. 2008 Aug;43(2):194-9
references.pmid: 18572414
references.citation: Mycoses. 2008 Sep;51 Suppl 4:16-26
references.pmid: 18783560
references.citation: Exp Dermatol. 2007 Nov;16(11):936-45
references.pmid: 17927577
references.citation: Proc Soc Exp Biol Med. 1953 Feb;82(2):184-9
references.pmid: 13037840
references.citation: Br J Dermatol. 2000 Nov;143(5):1036-9
references.pmid: 11069516
references.citation: Diagn Mol Pathol. 2008 Dec;17(4):207-13
references.pmid: 18936709
references.citation: Br J Dermatol. 2005 Jan;152(1):52-9
references.pmid: 15656800